title: Long-term results of mitral valve reconstruction with Carpentier techniques in 148 patients with mitral insufficiency.
abstract: There have been few relatively complete follow-up studies of long-term mitral valve function after Carpentier-type surgical reconstruction. Between January 1980 and May 1986, 148 patients underwent Carpentier reconstruction for mitral valve disease (43% degenerative and 30% rheumatic). Operative mortality was 5.4% overall (1.2% for isolated mitral reconstruction), and follow-up (mean, 26 months) was completed for all survivors. Five-year survival from late cardiac death was 90.0%, as was 5-year freedom from postreconstruction mitral valve replacement. Postreconstruction mitral replacement was needed in eight patients, in only five for failure of repair. Follow-up echocardiographic studies on 83.2% (104 of 125) of eligible patients showed 92.3% were free of significant (3+ or 4+) mitral regurgitation. Freedom from mitral valve replacement or recurrent severe (4+) insufficiency was 84.4% at 5 years overall, but was lower for the rheumatic type of mitral disease than for the degenerative type (71.6% vs. 88.3%). At 5 years, 95.2% of patients were free from thromboembolism without the necessity for long-term warfarin (Coumadin) therapy. At follow-up, 95.3% of survivors had improved to New York Heart Association Class I or II. The functional durability of mitral reconstruction and consistently high level of freedom from late endocarditis and thromboembolic and anticoagulant complications support the value of the Carpentier method of mitral reconstruction for mitral insufficiency, especially insufficiency due to degenerative disease.
authors.affiliation: Department of Surgery, NYU Medical Center, NY 10016.
authors.forename: A C
authors.initials: AC
authors.lastname: Galloway
authors.forename: S B
authors.initials: SB
authors.lastname: Colvin
authors.forename: F G
authors.initials: FG
authors.lastname: Baumann
authors.forename: R
authors.initials: R
authors.lastname: Esposito
authors.forename: R
authors.initials: R
authors.lastname: Vohra
authors.forename: S
authors.initials: S
authors.lastname: Harty
authors.forename: R
authors.initials: R
authors.lastname: Freeberg
authors.forename: I
authors.initials: I
authors.lastname: Kronzon
authors.forename: F C
authors.initials: FC
authors.lastname: Spencer
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D004452:Echocardiography; D004697:Endocarditis, Bacterial / Q000209:etiology; D005500:Follow-Up Studies; D006801:Humans; D008722:Methods; D008875:Middle Aged; D008943:Mitral Valve / Q000601:surgery*; D008944:Mitral Valve Insufficiency / Q000150:complications / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011182:Postoperative Care; D011183:Postoperative Complications / Q000401:mortality; D013923:Thromboembolism / Q000209:etiology; D014859:Warfarin / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D010975:Platelet Aggregation Inhibitors; D014859:Warfarin